Oncolytics Biotech Inc (ONCY)
1.17
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
1.17
0.00 (0.00%)
After-Hours: 20:00
Oncolytics Biotech Net Income (Quarterly): -2.901M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -2.901M |
| September 30, 2023 | -7.396M |
| June 30, 2023 | -5.532M |
| March 31, 2023 | -4.758M |
| December 31, 2022 | -6.298M |
| September 30, 2022 | -3.376M |
| June 30, 2022 | -3.987M |
| March 31, 2022 | -5.349M |
| December 31, 2021 | -6.149M |
| September 30, 2021 | -3.868M |
| June 30, 2021 | -5.900M |
| March 31, 2021 | -5.077M |
| December 31, 2020 | -7.158M |
| September 30, 2020 | -5.064M |
| June 30, 2020 | -4.925M |
| March 31, 2020 | 0.2981M |
| December 31, 2019 | -14.70M |
| September 30, 2019 | -2.671M |
| June 30, 2019 | -3.926M |
| March 31, 2019 | -3.713M |
| December 31, 2018 | -3.644M |
| September 30, 2018 | -2.552M |
| June 30, 2018 | -3.264M |
| March 31, 2018 | -3.698M |
| December 31, 2017 | -3.731M |
| Date | Value |
|---|---|
| September 30, 2017 | -2.397M |
| June 30, 2017 | -3.233M |
| March 31, 2017 | -2.656M |
| December 31, 2016 | -3.904M |
| September 30, 2016 | -2.555M |
| June 30, 2016 | -2.003M |
| March 31, 2016 | -2.926M |
| December 31, 2015 | -2.618M |
| September 30, 2015 | -2.158M |
| June 30, 2015 | -3.131M |
| March 31, 2015 | -2.869M |
| December 31, 2014 | -3.324M |
| September 30, 2014 | -4.258M |
| June 30, 2014 | -4.325M |
| March 31, 2014 | -4.976M |
| December 31, 2013 | -5.518M |
| September 30, 2013 | -5.885M |
| June 30, 2013 | -4.906M |
| March 31, 2013 | -6.557M |
| December 31, 2012 | -8.565M |
| September 30, 2012 | -9.281M |
| June 30, 2012 | -10.08M |
| March 31, 2012 | -8.444M |
| December 31, 2011 | -11.41M |
| September 30, 2011 | -6.365M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-14.70M
Minimum
Dec 2019
0.2981M
Maximum
Mar 2020
-5.196M
Average
-5.064M
Median
Sep 2020
Net Income (Quarterly) Benchmarks
| Acasti Pharma Inc | -2.391M |
| Aurinia Pharmaceuticals Inc | -26.88M |
| Edesa Biotech Inc | -1.678M |
| Lexaria Bioscience Corp | -0.6495M |
| Xenon Pharmaceuticals Inc | -44.74M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.500M |
| EPS Diluted (Quarterly) | -0.0367 |
| Enterprise Value | 61.92M |
| Earnings Yield | -26.03% |